Vaxxinity, Inc. (VAXX)

Market Cap	2.53M
Revenue (ttm)	n/a
Net Income (ttm)	-56.93M
Shares Out	126.75M
EPS (ttm)	-0.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Open	0.0900
Previous Close	0.0900
Day's Range	0.0500 - 0.0900
52-Week Range	0.0010 - 1.5000
Beta	3.05
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About Vaxxinity

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer’s disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated α-synuclein in the brain to fight parkinson’s disease and other synucleinopathies, such as Lewy body dementia an...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2021
• Employees: 65
• Stock Exchange: OTCMKTS
• Ticker Symbol: VAXX